Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

0.9074 +0.0065 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,462,390
Open 0.9100
Bid (Size) 0.9001 (3)
Ask (Size) 0.9100 (48)
Prev. Close 0.9009
Today's Range 0.8890 - 0.9298
52wk Range 0.3600 - 2.105
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire

Performance

YTD
+37.99%
+37.99%
1 Month
-1.86%
-1.86%
3 Month
-33.28%
-33.28%
6 Month
-46.94%
-46.94%
1 Year
+133.50%
+133.50%

More News

Read More
Shankar Musunuri, CEO of Ocugen Inc. (NASDAQ: OCGN), to Present at NobleCon20
Via Investor Brand Network
Navigating 4 Analyst Ratings For Ocugen
Via Benzinga
A Preview Of Ocugen's Earnings
Via Benzinga
Peering Into Ocugen's Recent Short Interest
Via Benzinga
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen Secures $30 Million in Debt Funding
From Ocugen
Via GlobeNewswire
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
From Ocugen
Via GlobeNewswire
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
From Ocugen
Via GlobeNewswire
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
From Ocugen
Via GlobeNewswire
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
From Ocugen
Via GlobeNewswire
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Ocugen
Via GlobeNewswire
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
InvestorNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.